QUOTE AND NEWS
Market Intelligence Center  Mar 3  Comment 
After closing Monday at $108.42, BioMarin Pharmaceutical (BMRN) presents an attractive opportunity to get a 9.81% return in just 136 days, which is an annualized return of 26.33% (for comparison purposes only). To enter this trade, sell one Jul....
Motley Fool  Feb 26  Comment 
2017 could be the year for the orphan-drug maker.
Benzinga  Feb 25  Comment 
In a report published Wednesday, Evercore ISI analyst Mark Schoenebaum discussed the latest developments at BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). In the report, Deutsche Bank noted, "BMRN just reported 4Q and FY14 results, as well as...
Benzinga  Feb 20  Comment 
In a report published Friday, Wedbush Morgan analyst Liana Moussatos maintained a Neutral rating on BioMarin Pharmaceutical Inc (NASDAQ: BMRN), with a price target set to $102. The company is scheduled to report its 4Q14 results after market close...
Market Intelligence Center  Feb 13  Comment 
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on BioMarin Pharmaceutical (BMRN) that includes 8.81% downside protection. Sell one contract of...
Motley Fool  Feb 2  Comment 
Three Fools outline the reasons they think these biotech stocks could be top buys in February.
TheStreet.com  Jan 27  Comment 
TheStreet is providing FREE access to Jim Cramer’s charitable trust (Action Alerts PLUS) and his premium articles on Real Money this weekend. Please register here. Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad...
Benzinga  Jan 16  Comment 
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) pipeline and existing products could drive a doubling of revenue every four years, an analyst said Friday. Nomura's M. Ian Somaiya boosted his target on the company by 6 percent to $123, maintaining...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki